Abstract
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p
| Original language | English |
|---|---|
| Pages (from-to) | 1235-1243 |
| Number of pages | 9 |
| Journal | Acta tuberculosea Scandinavica |
| Volume | 47 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB. / Tiberi, Simon; Payen, M. C.; Sotgiu, Giovanni; D'Ambrosio, L.; Guizado, Valentina Alarcon; Alffenaar, Jan Willem C; Arbex, Marcos Abdo; Caminero, Jose A.; Centis, Rosella; De Lorenzo, Saverio; Gaga, Mina; Gualano, Gina; Arias, Aurora Jazmín Roby; Scardigli, Anna; Skrahina, Alena; Solovic, Ivan; Sulis, Giorgia; Tadolini, Marina; Akkerman, Onno W.; Arrascue, Edith Alarcon; Aleska, Alena; Avchinko, Vera; Bonini, Eduardo Henrique; Marín, Félix Antonio Chong; López, Lorena Collahuazo; De Vries, Gerard; Dore, Simone; Kunst, H.; Matteelli, Alberto; Moschos, Charalampos; Palmieri, Fabrizio; Papavasileiou, Apostolos; Spanevello, Antonio; Vasquez, Dante Vargas; Viggiani, Pietro; White, Veronica; Zumla, Alimuddin; Migliori, Giovanni Battista.
In: Acta tuberculosea Scandinavica, Vol. 47, No. 4, 01.04.2016, p. 1235-1243.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB
AU - Tiberi, Simon
AU - Payen, M. C.
AU - Sotgiu, Giovanni
AU - D'Ambrosio, L.
AU - Guizado, Valentina Alarcon
AU - Alffenaar, Jan Willem C
AU - Arbex, Marcos Abdo
AU - Caminero, Jose A.
AU - Centis, Rosella
AU - De Lorenzo, Saverio
AU - Gaga, Mina
AU - Gualano, Gina
AU - Arias, Aurora Jazmín Roby
AU - Scardigli, Anna
AU - Skrahina, Alena
AU - Solovic, Ivan
AU - Sulis, Giorgia
AU - Tadolini, Marina
AU - Akkerman, Onno W.
AU - Arrascue, Edith Alarcon
AU - Aleska, Alena
AU - Avchinko, Vera
AU - Bonini, Eduardo Henrique
AU - Marín, Félix Antonio Chong
AU - López, Lorena Collahuazo
AU - De Vries, Gerard
AU - Dore, Simone
AU - Kunst, H.
AU - Matteelli, Alberto
AU - Moschos, Charalampos
AU - Palmieri, Fabrizio
AU - Papavasileiou, Apostolos
AU - Spanevello, Antonio
AU - Vasquez, Dante Vargas
AU - Viggiani, Pietro
AU - White, Veronica
AU - Zumla, Alimuddin
AU - Migliori, Giovanni Battista
PY - 2016/4/1
Y1 - 2016/4/1
N2 - No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p
AB - No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p
UR - http://www.scopus.com/inward/record.url?scp=84964054940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964054940&partnerID=8YFLogxK
U2 - 10.1183/13993003.02146-2015
DO - 10.1183/13993003.02146-2015
M3 - Article
VL - 47
SP - 1235
EP - 1243
JO - European Journal of Respiratory Diseases
JF - European Journal of Respiratory Diseases
SN - 0903-1936
IS - 4
ER -